Eun Yang
Stock Analyst at Jefferies
(0.52)
# 4,124
Out of 5,182 analysts
31
Total ratings
35.29%
Success rate
-23.66%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RIGL Rigel Pharmaceuticals | Upgrades: Buy | $23 → $42 | $30.51 | +37.66% | 1 | Nov 5, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $566.99 | -23.81% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $6.46 | +23.84% | 2 | May 14, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $56 → $12 | $8.78 | +36.67% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $74.52 | -55.72% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.73 | +1,518.50% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $44.90 | -39.87% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $1.92 | +264.58% | 1 | Feb 10, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $3.67 | +581.20% | 1 | Nov 14, 2022 | |
| NCNA NuCana | Maintains: Buy | $105,000 → $15,000 | $2.21 | +678,633.03% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.76 | +1,320.45% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $39.51 | -11.41% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $340.18 | -35.33% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $180.67 | +71.58% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $127.75 | -37.38% | 3 | Jul 11, 2017 |
Rigel Pharmaceuticals
Nov 5, 2025
Upgrades: Buy
Price Target: $23 → $42
Current: $30.51
Upside: +37.66%
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $566.99
Upside: -23.81%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $6.46
Upside: +23.84%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $56 → $12
Current: $8.78
Upside: +36.67%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $74.52
Upside: -55.72%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.73
Upside: +1,518.50%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $44.90
Upside: -39.87%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $1.92
Upside: +264.58%
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $3.67
Upside: +581.20%
NuCana
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $2.21
Upside: +678,633.03%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.76
Upside: +1,320.45%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $39.51
Upside: -11.41%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $340.18
Upside: -35.33%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $180.67
Upside: +71.58%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $127.75
Upside: -37.38%